Infant Bacterial Therapeutics AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IBT-B.ST research report →
Companywww.ibtherapeutics.com
Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants.
- CEO
- Staffan Stromberg
- IPO
- 2016
- Employees
- 8
- HQ
- Stockholm, SE
Price Chart
Valuation
- Market Cap
- $699.07M
- P/E
- -10.14
- P/S
- 0.00
- P/B
- 8.76
- EV/EBITDA
- -7.97
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -63.91%
- ROIC
- -90.41%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-65,166,000 · 52.40%
- EPS
- $-4.84 · 52.36%
- Op Income
- $-68,995,000
- FCF YoY
- 0.00%
Performance & Tape
- 52W High
- $84.30
- 52W Low
- $43.25
- 50D MA
- $52.13
- 200D MA
- $55.06
- Beta
- -0.47
- Avg Volume
- 8.36K
Get TickerSpark's AI analysis on IBT-B.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our IBT-B.ST Coverage
We haven't published any research on IBT-B.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IBT-B.ST Report →